Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 16/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554430 | 1.00 | EPHX2 (0.43) | EPHX2CFDCYP2C9HTR2CCXCR2 | |
| Hydrochloric Acid SCHEMBL20378176 | 0.99 | EPHX2 (0.43) | EPHX2CFDCYP2C9HTR2CCXCR2 | |
| Hydrochloric Acid SCHEMBL20378179 | 0.99 | EPHX2 (0.43) | EPHX2CFDCYP2C9HTR2CCXCR2 | |
| Hydrochloric Acid SCHEMBL28859842 | 0.93 | HTR2C (0.49) | EPHX2CFDCYP2C9HTR2CCXCR2 | |
| SCHEMBL29840673 | 0.83 | CFD (0.47) | CFDCYP2C9 | |
| SCHEMBL18591255 | 0.83 | CFD (0.47) | CFDCYP2C9 | |
| Hydrochloric Acid SCHEMBL18555534 | 0.82 | CFD (0.46) | CFDCYP2C9 | |
| Hydrochloric Acid SCHEMBL29546173 | 0.82 | CFD (0.46) | CFDCYP2C9 | |
| SCHEMBL19234185 | 0.81 | CFD (0.45) | CFDCYP2C9 | |
| SCHEMBL29840887 | 0.81 | CFD (0.45) | CFDCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340982-B1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3340982-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035408-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | CFD, TFPI, CFH | EPHX2 1449/4885CFD 1/4885CYP2C9 2862/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | EPHX2 1449/4885CFD 1/4885CYP2C9 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.